The triazole antimycotic terconazole was first synthesized at Janssen Pharmaceuticals. Terconazole is a broad-spectrum triazole antimycotic with activity against most species of pathogenic fungi.

Pharmacokinetics

After intravaginal application, 5 – 16% of the dose is aborbed. The substance is extensively metabolized and eliminated via the urine and feces.

Indications

Topical treatment of mycoses of the skin induced or sustained by fungi such as dermatophytes and yeasts. In addition, terconazole is indicated for theraphy of vulvovaginal mycoses caused by Candida species and Candida (Torulopsis) glabrata.

Side Effects

CNS. After intravaginal application of terconazole, a flu syndrome (fever, headache, hypotension) was observed. Local irritations and allergic reactions may occur in rare cases and are mainly due to the galenic formulation.